P GAUDREAULT . Nonsteroidal anti-inflammatory agents in the treatment of asthma in children. Can Respir J 1995; 2(Suppl A): 24A-31A.
compound 48/80, and the calcium ionophore A 23 187 (2) (3) (4) .
Thi s mast cell membrane stabilization appears to be rL·lated to the phosphorylation or a membrane prote in that can modulate calcium intracellu la r inrlux (5) . Other modes of action involve the reduction of brnnchoconstriction by an action on the afferent arm of the nL·rvous reflexes and the reduction in the activity of lung irritant receptors and the inhibition of C fibre nerve endings ( (1 ) . T he increasing emphasis on the inflammatory component of airway obstruction and its relationship with bronchial hype rreactivity has !eel to the study of sodium cromoglycate in mode ls invulving in!bmmatory ce lls. The administrat ion ol'smlium cromoglycalc can prevent the activation of peri phera l blood ne utrophils and eos inoph ils following immunologi cal and nonimmunological stimuli (7 .8) . Others have shown that its prolongcJ admi nistration has res ul ted in a significant decrease o r eosinophils in bronchoa lveolar lavage fluids (LJ). This potential of sodium eromoglycate to red uce inflam mation may he more important than its mast ce ll stabilization in regard to its antiasthrnatic e ffect.
Sodium cromoglyG1tc has no intr insic bronchodi lator properties. In vitro, it reduces the contraction of smooth muscle induced by ace tyldmlinc, his tam ine, se rotonin , hrndykinin. and prostag landin (PG) F2. FurthL'llll(lrl', it polentiates smooth muscle relaxation induced by isoprotereno l. aJrcnaline, PG E2 and salbutamol (I). In vivo, sodi um crornoglycate inhibits hronchoconsl riction produced by e xerci se, the inhalation or cold air. sulph ur dinxidc, the nebul ization of distilled waler and le ukotrie ne 04 (6. 10-15).
Clinical pharmacology
Acute bronchial challenge: T he admini strati on or sodi um cromog lycale can prevent the immed iate and late asthmatic response to anti gen challenge. Altounyan ( 16) demonst rated that the admi nistration of sodium cromoglycatc before an antigen chal lenge inhibited the fall in fo rced ex pi ratory voluml' in I s (FEY 1 ). This protective l'f'fect dim ini shed. hmv-eVL'r, when sodium cromog lycale was g iven afte r the ant igen Can Respir J Vo l 2 Suppl A March 1995 chall enge. Furthem10re, th is protectiv e e ffect 01 · sodium cromog lycate lessened when the time be tween its inhal ation and antigen challe nge was increased ( 16). A lthoug h resu lts on sodi um cromoglycate's protec tive effec t against constricting agents such as methacho line and histamine are con n ic ting (I), most studies have demo nstrated its e fficacy aga inst nume rous bronchocon stric ting agents such as carbacho!, sulphur diox ide, metabisulph ite. e xe rcise and cold air (I).
Late asthmatic response: Many ast hmatics unde rgo a second bronchoconslrictive response 4 to 12 h follo wing inha latio n c hallenge wi th antigen. Th is phe nomenon is known as the delayed o r !ate as thmatic response. Sodium cromog lycate also blocks this late asthmatic response when given be fore ch a lle nge with a varie ty of anti gens. Since the !ate ast hmatic response is associated with severe ast hma and COITe lates w ith inc reased bronc hial hypeITeac tiv ity , sollle authors fee l that the role of sod ium cromog lycate in preventing thi s late reaction may be one of the keys to its ability lo con trol and improve chron ic as thma.
Bronchial hyperreactivity: Airway hyperreactivity is a charac teri sti c feature of asthma and the degree of bronchial respons ive ness. as measured by his tami ne challenge, has been shown to corre late with the severity of ast hma. Desp ite some c o nflicti ng res ults, most stu dies have de mons trated that long tem1 administration of sodi um cromog!ycate c111 red uce bronchi al hyperreactiv ity in both adu lts and chi ldren ( 17) . T he resu lts of se vera l ped iatric studies are presented i11 Table I. Clinical efficacy: Several studies have in vesti gated the e fficacy of sodium cromogl ycate in the treatment of asthma ( 17) . In ped iatric studies , sodium c ro moglycate was shown to be supe rior lo pl ace bo in improving pulmonary functi on tests a11J i11 reducing ast hmatic symptoms, phy.sician assessed asthllla severity and concomitant bronchocl ilator use (beta2ago nis1s and theophy lline) ( 18-20). T he a mount of sodium c romoglycate deposited in the lung and subseque ntly adsorbed de pends upon th e dose admini ste red , the deli very system a nd the prope r technique. There is no di rec t correlatio n. however, between clinical effi cacy and e ither the amount or drug deposited in the lun g or cromolyn blood concentrations ( I). Sodium cronwg lycate has also heL'll compan:d with othe r medications such as tlll'ophyll inc and steroids in the treatmen t or asthma. Some o f the comparative studies between sodium cromoglycate and thcophyll ine that were perfom1ed in children are sum ma ri zed in Table 2 ( I) .
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These studies clearly demonstrate that sod ium cromog ly-c1te and th eophylli ne are e4uall y e fficacious in the cont rol or asthma symptoms and in improving pulmonary function tests; however, theophylline caused more gastrointestina l and central nervous system side effects. In addition. sodium crornoglycate has an adv antage over theophylline for long te rm use beca use o f its ability to decrease bronchial hyperreactivity.
Hoth theophylli ne and sodium cromoglycate in hi bit exe rcise-indu ce d as thma hut ;ire les s e fficacious than be ta2adrenergic agents. Sodium cromoglycatc should be se lected over these agents if a patient requi res the ir use more tha n two to th ree ti mes a wed.
Early clin ica l studie, of steroid dependent asthmati c pati ents suggested that the addition of sodiu m cromog lycate co uld have a corticosteroid sparing effect (21.22 ) . More recent data. however. could not confirm these res ults and we re not ahle to demonstrate any be ne fit from combined sodium crornoglycate and corticosteroid therapy (23-25). Based on these resu lts. there appears to be no advantage in presc rib ing sodium cromuglycate to steroid de pendent patie nts.
Pediatric dose
Sodium nomoglycate is availabl e in Canada in three forms -20 mg powdered capsule de live red via th e Spinhalcr (Fisons) apparatus, I% solution containing 20 mg o f sodium cromoglycate per 2 mL of di stilled water delive red by a compresso r-driven nebuli zer. and a pressurized me tereddose inhaler that releases I mg pe r actuation.
No pediatri c study has been done to evaluate a possi ble dose-respo nse effect for sodium crornoglycatc; those carried t>ut only compared si ngle doses admini ste red wi th diffe re nt apparatus. In one study (2 (1 ). 2 mg doses or sodium cromoglycate admini ste red via metered close inhaler and 20 mg administered via a Spi nhaler apparatus we re both e ffi cac ious in preventing exerci se-induced asth ma. In another study ( 27) . doses of 2 mg sodium cromoglycate admini ste red qid via me te red close inlwll'r and 20 mg administered qid via a 26A Spinhakr apparatus wcrc equally ellicacious i11 controlling c hronic asth ma symptoms. Carrasco and Sepul veda (28 ) noted, howeve r. tha t a lthough beneficia l effect s of sodium c romoglycate we re eq ui valent at the end of the study period . they appea red soone r in patients rece iving IO mg qid via mete red dose inhaler instead of 2 mg qid via mete red dose inhaler.
Res ults from adult studies on close-response e ffec ts are conflicting ( 17) . Diffe re nces noted in adults can be partially explained by the fact that a dose-response effec t seems to depe nd on the type of stimuli used to in duce bronchospasm. Some authors have demonstrated that the duration of the e ffec t of sodium c romoglycatc is partially re lated to the amount g iven and the type of challenge stimulus used . Patel and Kerr (3 I) noted that doses of 20 mg and 40 mg of sodium cromoglycate continued to provide a partia l protecti on aga inst an exercise-induced fall in FEYt 270 rnim after tlll'ir adm inistration. whe reas the effec t o r 2 mg had worn off.
Severa l cl in icians fe el th at the Europea n form ulation ol 5 mg of sodium crornog lycate del ive red by a metered close inhaler is more e fficac ious th at the I mg available in North America. There a rc no ped iatri c studies . how ver. to support that conte ntion.
Sodi um crornoglycatc is very sa fe . T he median parenteral lethal dose for di ffe rent animal species is 4000 mg/kg (I). NEDOCROMIL SODIUM Nedono111il sodium is the Jisodium salt ol'a pyranoq11i110line dicarhoxylie acid (32). Ncdoerornil sodium is a pale yellow powder_ hydrophilic with a molec ular weight of 415. Following inhalation of nedocrnmil sodium in healthy volunteers, plasma concentrations rise rapidly and mean pea k levels are reached in 20 rnins. whereupon they plateau for I h foll owed hy a decline in plasma level s. These plasma levels suggest the persistence of nedocrornil in the lungs for a longe r period than wo11ld be ex pected and may account for the rapeutic efficacy with a twice daily regimen (33).
Mechanism of action
Nedocromil sodium is a cromolyn-like agent with antiall e rg ic and anti -inlbmmatory properties. In a ni mals. nedocrnmil sodium was ahle to inhibit ra1tially bronehoconstriction induced by bradykinin, which is rartially related to an inhibition of the axonal rel1ex. anJ other specific antigens such as ascaris in !he ascaris-sensitive k/acaur ,ll'cloicli's monkey (34).
In vitro studies have shuwn that ncd,>eromil sodium is ,t more potent inhibitor than sodium cromoglycate in the re-leasL' of hi stamine , leukotricne C4 and prostagland in D2 in primate Jung mast cell s. and of histamine in human mast cells (.'ti.36). It ean al so prevent chrn1otactic and inflammatory mediator release from animal derived e!Tector cells such as granulocytcs. monocytes, macrophages, eosinuphi Is. platelets and mast cells (37.38).
Clinical pharmacology
Acute and late bronchial challenge: Results from numerous adult studies have demonstrated that nedocromil can prevent hronchospasm induced by exercise, fog, cold air. adenosine , sulphur dioxide and anti gen (32,39-42). Moreove r, it was also more efficacious than sodium cromoglycate in these studies. In pediatrics there is a paucity uf such ~tudies. Hmvever. till' few stud ies c,mcluctcd on this subject dcmon strall' that 11cdocromil was also able to prevent exercise-induced asthma in children (Table 3) prevention of exe rci se-induced asthma was cornp,tred with sod ium cromoglycate efficacy. both treatments produced a similar response ( 46). Simi lar to sodium cromoglyeate. nedocromil sod ium can inhibi t the late bronclwconstrictor response to allergen challenge (47). Bronchial hyperreactivity : Airway hyperreactivity cnm monly occurs following anti gen exposure during the pollen season. Studi es in adults have shown that nedocromil sodium can significantly deerease bronchial hype ractivity (48,49). Clinical efficacy: Numero us studies in adults have investigated the efficacy of ncclocromil sodium in the treatment or asthma. Recently. Edwards and Stevens (50) pu blished a meta-analysis of all known placebo controlled. double-blind. randomized therapeutic trials. Overall , their meta-analysis demonstrated that nedocromil sodium decreased the use of inhaled bronchodilators. reduced day-and nighttime symp-tom s of asthma and improved pulmonary fun ction tests such as mean daily peak expiratory fl ow rate and FEY 1 (50). Prel iminary studies in children reported an improvement in lung function and a dec rease in bronchodil ator requ ireme nts during the administration ofnedoeromil sodium (32). Studies in ad ults on the steroid sparing effec t of neclocromil havL' ge nerated conflicting data (51 -54) . Such data are not availabl e in pediatrics.
In vitro and adult studies suggest that nedocromil sodium is a more potent anti -infl ammatory and antiasthmatic age nt than sodium cromoglycatc (32,35.36.39-42). There are no data in the pedi at ric li terat ure to confim1 or refu te that conclusion. In the absence or thi . s information it is difficult lo clete nni ne the exact role and place or nedocrornil sodium in the treatment ol' as1hma in children.
Pediatric dose
Nedocrom il sodium is only available in a metered dose inhaler formulation. There is no dose-respon se effect fo r nedocromil sodium in children. The recommended dose is 4 mg qid. When the patie nt is stabili zed. this dose can he tape red to bid (32).
KETOTIFEN
Ketotifen is a benzocycloh eptathiophen derivative wit h antiallergic and anti anaphylactic properties. Ketotikn is rapidl y absorbed followin g oral administration. and peak plasm a leve ls arc reached within 2 to 4 h_ There is no es tabli shed correlatilln belwL·en ke1oti fen blood concentration and its 27A 
Mechanism of action
Our knowledge on ketoti fen 's mech:.inism of action is limited and pre sently under investigation. Expe rimental evidence sugges ts an tian:.iphylaclic properties substantiated by ketotifen's ability lo inhibit !he release or mediators of anaphylaxis such as lhc slow reacting substance or anaphylaxis, and the inhibition or calcium uptake in isolated mast cells and in smooth muscle (56) (57) (58) . In animal models of pass ive c1ttaneous :lllaphybxis, kc!Olifen inhibits bolh passive cul:meous anaphylaxis and histamine-induced reactions (:'io,57) .
Ketotifen also 1.:xhibils some anliaslhrn:.itic prope rtie s. In animal . •audies kclolikn adminislralion before aerosol challenge atte nuated hronchoalveolar cosinophilia (59) . Eosinophil recruitme nt in !he lracheobronchial lrce and their activation within the lung releases cyloloxic proteins and potent inflammatory med iators (leu kotriene C4, supe roxidc 102-], platelet-activating factor) !hat will precipitate a cascade o r e ve nts that will subsequently lead lo bronchial hyper-28A reac livily (55.60). Although ke tot ife n has no bronchodilator properties , it appear-10 be capable of increasing both the affin ity for !he bcui2-adre nerg ic receptors and cAM P intracellular concentrations (55).
Clinical pharmacology
Acute bronchial challenge: Ke totife n administration has been sho w n lo inhibit the bronc hoconsrriction caused hy e ither histamine or allergen challenge but w ill not prevent bronchospasm induced by e ither melhacholine inh:.ilalion or exerc ise (55,61 -64 ). Althoug h !he num ber of studies on acute bronchial challenge in children is ve ry limited. !hey generalcd resu lts similar lo those obtained in adults (55 ,65).
Clinical efficacy:
Studies des igned to ,' valuate the efficacy of ke toti fe n in the treatment or asthma in children have generated conflic ti ng results (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) . T he parameters used to eval uate the efficacy of ketolifen in the lrealmenl of asthma were mainly based on analysis of patients' symptom diaries and bronchodilator requirements. T he majority (66% ) o f the studies (T able 4) reported a dec rease in both frequency of symptoms and use of bronchodilators, s uch as 1heophyllinc or beta2-agoni sts . in pat ients receivi ng oral ketotifen . These improvements occurred in mos! instances following long term administrat ion (ie, more than eight weeks). In genera l, children responding to ketotifen experienced fewer interrupti ons of their daytime activities and fewer nighttime symptoms (71.74) . The majority of patients or th e ir pare nts favoured ketotifen over place bo in their glnhal assessment of the trial.
The information on the effect of long tcm1 kctotifen therapy o n s pirometric measures of airway obstruct ion is limited. In c>11c study ketotifen treatment did not improve forced expiratory flow rate at 25 to 75 % of forced vital capacity (FYC), but increases in FEY I and FYC reached statistical s ignificance after s ix and l O weeks of ketotifen the ra py, respectively (75) . In several studies, ketotifen treatme nt was not associated with improvement of peak expiratory flow rates (74.76 .XO) .
There are few studies comparing ketotifen with sodium cromoglycate and none with nedocromil sodium (82,8 3) . In studies where sodium cromog lycatc and ketot ifen we re administered concomitantly, the addition of ke toti fe n did not provi de any additional benefit to the patient's treatment (55.76). In studies comparing h ·totife n with sodium cromogl ycate, the two drugs produced similar improvement in asthma symptoms (82 ,83) .
Ketotifen prophylax is to prevent the developm e nt of asthma in selected infants and yo ung children has been e valuated (55,84). Iikura ct al (84) evaluated the prophylactic effect of keto tifen against th e onset of asthma in 12 l infants with atopic dermatiti s witho ut an y histo ry suggestive of asthma. Sixty -one patients received ketotife n (0.8 mg for children weighing less than 14 kg, and 1.2 mg for children weigh ing 14 kg or more). D uri ng the one-year study period. asthma was observed in e ight children front the kctoti fen gro up ( 13. l 'k) and in 25 children from the placebo group ( 4 1.6% ) (P<0.00 I). Although the results of thi s study are very interesti ng, further inv est igations are require d before broad use of ketotifen in atopic children can be recommended to pre vent the development of asthma.
Kctotifen is generally well tolnated, and the most common sick effects are weigh t gain of 2.8 to 3.3 kg over a one-year period in chi!Jren less than 12 years of age and drowsi ness, which declines over one to two weeks (55 ).
Pediatric dose
Children between s ix months and three years of age should he admini ste red 0.5 m g of ketotifen twice da ily, wh ile l mg should be given to those over three years of age (55).
CONCLUSION
Nonsteroidal ;1nti-intbm111atory agents dearly have a role to play in pediatric asthma. Sodium cromoglycate and nedonomil sodium are two cllicaeious a ntiasthmatic agents that should he used in the tre atment of c hronic mild to mode rate asthma. Several in vitro and adult studies suggest tha t neck>cromil sodium see ms to be more potent than sodium cromoglycate; howeve r, similar data arc lac"-ing in the pL'diatric population. Therefore. based on the information available in the pediatric literature, sodium cromoglycatc could be the Can Respir J Vol 2 Suppl A March 1995 OT age nt of first choice, hut nedoc romil sod ium is cntainly a very acce ptabll' alte rn a tive.
Sodium cromoglycate a nd nedocromil sodium can prcwnt exercise-induced as thma but are less efficacious than beta2-acl renoreceptor agents . T he y s hould be favoured, however. in patiL'nts requiring more than one or two treatments per wee k. The optimal ped iatric dose of nedocromil sodium seem.
t\l he 4 mg qid. A lthough the administration of 20 mg of sodium cromoglycate via a Spin haler apparat us or by nebuli-1ation qid is adequate, 2 mg of sodi um cromoglycate administered with a m etered dose inhaler qid may not be optimal for all patients.
Since sodium cromoglycate is as efficacious as theophylline and produces s ignifi cantly fewe r side e ffects, it should be favoured in the treatme nt of th e chronic asthmatic requiring one of these two medications.
The precise role of ketotifen in the treatment of mild chronic asthma rema ins to be determ ined. Its rol e in the 'early pre ventio11' of the dcVL'lopm e nt of asthma merits further in vestigations.
